CLM-103 / Yooyoung Pharma, CellabMed - LARVOL DELTA

Phase I trial of an IL13Rα2-targeted CAR-T cell therapy for recurrent malignant glioma: Clinical results and pharmacokinetics (ESMO 2025) - P1 | "Conclusions Intravenous IL13Rα2-targeted CAR-T therapy was well tolerated and demonstrated preliminary safety. Further studies are warranted to optimize dosing, preconditioning regimens, and exploratory biomarkers for efficacy evaluation."

CAR T-Cell Therapy • Clinical • IO biomarker • P1 data • PK/PD data • Brain Cancer • Glioma • High Grade Glioma • Oncology • Solid Tumor • IL13 • IL13RA2

CellabMed, selected by the Ministry of Food and Drug Safety's 'Bio Challenger' program… Support for CAR-T treatment development [Google translation] (Nate) - "CellabMed announced on the 18th that CLM-103, a solid tumor CAR-T cell therapy that targets specific antigens of malignant brain gliomas including glioblastoma, was selected for the Ministry of Food and Drug Safety's Bio-challenger program...The BioChallenger Program is a project by the Ministry of Food and Drug Safety to promote the development of innovative, cutting-edge biopharmaceuticals for unmet medical needs, and to support their commercialization....Ministry of Food and Drug Safety actively participates in the entire development process of BioChallenger, including setting product development goals, clinical trials, and commercialization process design, and supports product development."

Clinical data • Commercial • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor

A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I) (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: CellabMED

CAR T-Cell Therapy • New P1 trial • Brain Cancer • Glioma • Oncology • Solid Tumor

A Novel CAR-T Cell Therapy Strategy to Inhibit Hepatocyte Growth Factor in Solid Tumor (ASGCT 2022) - " To examined efficacy of YYB-103 CAR-T and/or anti-HGF monoclonal antibody, in vivo experiment was performed in orthotopic xenograft mouse model using HGF-overexpressing ovarian cancer cell line A2780/IL13Rα2. Our experimental results showed that inhibition of HGF could be one strategy to improve the efficacy of CAR-T in solid tumors. Further study is ongoing to confirm experimental evidences that our new type of CAR-T, YYB-101 scFv-releasing CAR-T, actually acts on the immunosuppressive tumor microenvironment of solid tumors."

CAR T-Cell Therapy • Brain Cancer • Glioblastoma • Hematological Disorders • Hematological Malignancies • Oncology • Ovarian Cancer • Solid Tumor • CD8 • IFNG • IL13RA2 • MET

GC Cell inks Korea's 1st CDMO agreement for solid CAR-T therapy (Korea Biomedical Review) - "GC Cell said that it has signed a contract development and manufacturing organization (CDMO) agreement with Cellab Med to produce the latter's investigational drug for a solid cancer chimeric antigen receptor (CAR)-T treatment....Under the accord, GC Cell will produce and test the quality of Cellab Med's CAR-T treatment, YYB-103, planned for use in phase 1 clinical trials."

Licensing / partnership • Oncology • Solid Tumor

Phase 3 clinical trial of Roche Korea’s immuno-oncology drug ’Mosunetuzumab’ concurrently administered [Google translation] (Health Korea News) - "CelllabMed is conducting a phase 1 clinical trial of 'YYB-103' at the National Cancer Center. To evaluate the safety and tolerability of IL13Rα2-specific Chimeric Antigen Receptor-T Cell (CAR-T) 'YYB-103' in patients with recurrent malignant glioma who have failed standard therapy....Seoul Asan Medical Center conducts researcher clinical trials of 'Tocetaxel', 'Oxaliplatin', and 'S-1' (Tegafur, Gimeracil, Oteracil potassium complex) at this institution. This study was conducted on 'docetaxel', 'oxaliplatin', and 'S-1' as an adjunctive chemotherapy in 63 patients with gastric cancer with unresectable locally advanced or distant metastasis limited to lymph nodes."

New P1 trial • Gastric Cancer • Gastrointestinal Cancer • Glioblastoma • Glioma • Oncology

Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study. (PubMed, Front Immunol) - "Notably, YYB-103 CAR T cells exhibited effective blood-brain barrier crossing, suggesting compatibility with i.v. administration rather than intracranial injection. Additionally, the high H-score for IL13Rα2 in glioblastoma, especially in conjunction with the poor prognostic markers of wild-type isocitrate dehydrogenase-1 (IDH-1) and unmethylated O -methyl guanine methyl-transferase (MGMT), could be used to determine the eligibility of patients with recurrent glioblastoma for a future clinical trial of YYB-103 CAR T cells."

CAR T-Cell Therapy • Journal • Preclinical • Brain Cancer • Glioblastoma • Glioma • Immunology • Oncology • Solid Tumor • IDH1 • IL13 • IL13RA2

Celllab Med completes 23.3 billion Series B funding [Google Translation] (thebell) - “Accelerate clinical trials for colorectal cancer treatment, focus on expanding GMP-grade manufacturing facilities. Celllab Med has completed a series B investment worth 23.3 billion won. CelllabMed plans to use the funds raised for the expansion of indications for the antibody treatment CLM-101 (existing YYB-101), which is its core pipeline, and biomarker discovery. Celllab Med attracted 10 domestic institutional investors in this Series B round. Existing investment institutions, Kolon Investment and Wooshin Venture Investment, made follow-up investments (follow-on). K2 Investment, NH Investment & Securities, TS Investment, Aion Asset Management, Tigris Investment, Fine Value Asset Management, Korea Investment & Securities, and Hanwha Investment & Securities participated as new investors. It succeeded in attracting additional investment two years after it raised 10.5 billion won in Series A investment in 2019. The total amount of investment that the company has...

Grant • Colorectal Cancer • Oncology

[VIRTUAL] Development of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells against Malignant Glioma (ICBMT 2021) - "A number of IL13Rα2-targeting therapies, including CAR-T-targeting IL13Rα2, IL13Rα2-targeted immunotoxins, IL13 expressing virus, anti-IL13Rα2 antibody therapy, and IL13Rα2-targeted tumor vaccine, have been given in clinical trial and have proven to be safe. In this study, we tried to verify the efficacy of newly developed YYB-103, an IL13Rα2-targeted CAR-T, using modified IL13 as an antigen-binding domain, which lowered the binding affinity for IL13Rα1 expressed in normal cells in in vitro and in vivo model, and the possibility of intravenous administration of YYB-103."

CAR T-Cell Therapy • IO biomarker • Brain Cancer • Glioma • Oncology • Solid Tumor • IL13 • IL13RA2